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Abstract
Antibodies are large Y-shaped proteins which are used by immune system to identify
and neutralize pathogens. Monoclonal antibody therapy is used to treat different patient
conditions. There are problems associated with the manufacturability and deliverability of
mAb solutions due to the viscous nature of the protein. The viscosity of antibody solutions
increases with the increase in concentration and decreases with applied shear. We want to
know why these behaviours are seen and to address this problem we have developed a theory
describing the rapid viscosity increase with increasing concentration. We use the polymer
theory to explain this behaviour. Here antibodies are treated as polymers. The length of
the polymer depend on the aggregation. The reptation time increases approximately as the
cubic power of size of aggregate (N3). We see the shear thinning behaviour is dependent
on the Ab-Ab binding energy and find the relationship between the size of the aggregate
and the binding energy. We find aggregate size and morphology using several models for
Ab-Ab interaction sites. We use the head to head binding (fAb-fAb binding) model to
describe aggregation state in our viscosity theory. The size of the aggregate and hence the
reptation time is captured by the binding energy. When the binding energy increases the
zero shear viscosity increases and the reptation time decreases. Likewise when the binding
energy decreases the zero shear viscosity decreases and the reptation time increases. We
have yet to find the correct exponents for the shear thinning behaviour of different mAbs
which would be our future work.
Table of Contents
List of Figures . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . viii
Acknowledgements . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ix
1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1
1.1 Structure of Antibody and role in immune system . . . . . . . . . . . . . . 1
1.2 Monoclonal Antibodies and its uses . . . . . . . . . . . . . . . . . . . . . . 2
1.3 Problems Observed at High Concentration Biologic Formulation . . . . . . . 4
1.4 Introduction of Shear Thinning and Shear Thickening . . . . . . . . . . . . . 5
1.5 Classification of Polymer and Polymer Model of Antibody Viscosity . . . . . 6
1.5.1 Rouse Model . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8
1.5.2 Zimm Model . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9
1.5.3 Reptation Model . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10
2 Different binding Models of antibody . . . . . . . . . . . . . . . . . . . . . . . . . 13
2.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13
2.2 Binding models . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14
2.2.1 Head to head binding . . . . . . . . . . . . . . . . . . . . . . . . . . . 14
2.2.2 Head to tail binding . . . . . . . . . . . . . . . . . . . . . . . . . . . 15
2.2.3 Tail to tail binding . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16
2.2.4 Mixed binding . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 17
3 Shear thinning in Monoclonal Antibodies . . . . . . . . . . . . . . . . . . . . . . . 21
3.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 21
vi
3.2 Model . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 21
3.3 Introduction Of Shear . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 26
3.4 Model Behaviour . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 29
3.5 Fitted with experiment . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 29
3.6 Effect of temperature . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 31
3.6.1 Explanation of fit in figure 3.5 and figure 3.6 . . . . . . . . . . . . . 31
3.7 Conclusion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 34
vii
4    Bibliography  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .       35
List of Figures
1.1 Structure of Antibody . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2
1.2 Figure showing Shear thinning and shear thickening . . . . . . . . . . . . . . 6
1.3 Classification of polymers . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7
1.4 Classification of polymers . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7
1.5 Schematic view of Rouse model . . . . . . . . . . . . . . . . . . . . . . . . . 8
1.6 zimm model . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9
1.7 Entanglement to show the one direction motion due to reptation . . . . . . . 11
1.8 motion of chain along the tube . . . . . . . . . . . . . . . . . . . . . . . . . . 11
2.1 Head head binding for dimer . . . . . . . . . . . . . . . . . . . . . . . . . . . 14
2.2 Head tail binding for dimer . . . . . . . . . . . . . . . . . . . . . . . . . . . 16
2.3 Head tail binding for trimer . . . . . . . . . . . . . . . . . . . . . . . . . . . 17
2.4 Structure for binding of antibodies in different ways . . . . . . . . . . . . . . 18
2.5 Bar graph showing average size as a function of binding energy . . . . . . . . 19
2.6 concentration of monomers, dimers and trimers as the function of binding
energies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20
3.1 Head head binding in antibody polymer . . . . . . . . . . . . . . . . . . . . 22
3.2 chain retraction to equilibrium after strain . . . . . . . . . . . . . . . . . . . 26
3.3 Effect of Antibody-Antibody affinity on shear dependent viscosity . . . . . . 29
3.4 Effect of Nacl on the viscosity of mAbs . . . . . . . . . . . . . . . . . . . . . 30
3.5 Zero shear viscosity for different mAbs . . . . . . . . . . . . . . . . . . . . . 30
3.6 Effect of Temperature . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 31
3.7 Effect of Temperature . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 32
viii
3.8 fit for rod model and temperature dependent data . . . . . . . . . . . . . . . 33
3.9 Power law for NaCl dependence viscosity of mAbs . . . . . . . . . . . . . . . 33
ix
Acknowledgments
I would like to acknowledge my advisor Dr Jeremy Schmit, my research group, physics
department and Kansas State University for supporting me to do this work.
x
Chapter 1
Introduction
1.1 Structure of Antibody and role in immune system
The immune system protects the body against various germs which are present in the sur-
rounding. It protects the body by blocking the entry of microorganisms to the body and
if by any chance pathogens enter the body it attacks it by producing antibodies. Thus if
antigens attacks the immune system, antibodies act against it and will block its function.
Antibodies are large Y-shaped proteins which are used by immune system to identify and
neutralize pathogens like bacteria and virus1. Antibodies are also called Immunoglobin(IG)1.
They are heavy globular proteins with weight 550kDa1. They are made of two structural
units- two light chain and two heavy chain. There are five types of mammalian heavy chain-
γ, δ, α, ν and  with the classes IgG, IgD, IgA, IgM and IgE respectively1. Heavy chains
have approximately 1000 amino acids. Light chains have an approximate length of 211 to
217 amino acids. Each light chain and heavy chain are made of two regions, the constant
region and the variable region.1. The constant region is same in the antibodies of the same
isotopes whereas the variable region is different for the antibodies formed from different B
cells1.
Each antibody has unique target known as antigen. The antigen is the foreign substance
and it acts like a key for antibody in identifying the organism. The antibody contain three
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domains arranged in Y shaped. The antibody binds to specific antigens. The strength of
binding between antibody and antigen at the single binding site is known as the antibody’s
affinity for the antigen. The structure of an antibody is given below.
Figure 1.1: structure of Antibody. The figure in the left shows the molecular structure.Red
and blue are heavy chains whereas green and yellow are light chains of the antiboy. The
figure in the right is the schematic diagram (picture source wikipedia) . The antigen binding
domains are on the tip of the light chain and the heavy chain on the variable domain. The
constant domain are present in both heavy chain and light chain
1.2 Monoclonal Antibodies and its uses
Monoclonal antibodies (mAbs) are made by similar immune cells which are clones of a unique
parent cell1. For any substance monoclonal antibodies can be produced that specifically bind
to that substance which then is used to identify or purify that substance.
After the Nobel prize-winning breakthrough in physiology and medicine by Sir Bernard Katz
in the 1970s, the use of antibodies in medicine formed the scientific basis for its mass pro-
duction. By the mid 1980s, the FDA had approved the first therapeutic antibody, and by
the late 1990s, scientists and doctors had developed the first therapeutic antibody for cancer
(Genentech26). Today, biology has moved far beyond from a descriptive science to one that
allows engineers and scientists to develop new types of therapeutic antibodies. One way
certain therapeutic antibodies may work against cancer is by binding to proteins on the
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surface of tumor cells. Another way is cancer medicines that combine the targeting ability of
antibodies with chemotherapies designed to destroy cancer cells so the medicines are directly
delivered to cancer cells which decreases the effects of chemotherapy on healthy cells.
Molecular engineering has contributed to the clinical success of antibodies in the recent
years. With the help of antibody engineering, it has been possible to modify the molecular
size, binding affinity, specificity and effector function of antibodies. Nowadays engineers
are producing small antibody fragments. The large molecular size of IgG resulted in high
circulation time and high background in medical imaging22. The motive to develop small
antibody fragments was to make these molecules suitable for the radioimmunotherapy of
cancer. Thus antibody engineering has helped for improving their clinical utility
Antibodies are also used to reduce the risk of organ transplantation. When any organ like
lungs or kidneys are transplanted to the patient there is always risk of organ rejection. So
when patients with lungs transplantation are given antibodies against T cells ( cell that
plays vital role for immunity) within two weeks of lung transplantation the probability of
rejection decreases23. Antibodies also show promise as treatment of AIDS. The approach
called passive immunization is infusing antibodies in the patient’s blood. The studies are
ongoing and experts believe it will not only decrease the virus in the body but would cure
it24. There are many uses of mAbs. Some of them are summarized below.
1) They are used in diagnostic tests like pregnancy test kits(Biotech 1989). They are also
used in diagonosis of AIDS by ELISA test (oris 1987)
2) They are used in detection of cancer for example radioimmunodetection and radioim-
munotherapy of cancer. Nowadays many cancer drugs are based on technology of mAbs.3
3) They are used to alleviate the problems of organ rejection to those who have organ trans-
plant23
4) They are used in treating viral diseases traditionally considered untreatable. There is
evidence antibodies may lead to treatment of AIDS24
5) Researchers use mAbs to identify and to trace specific cells or molecules in an organism.
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1.3 Problems Observed at High Concentration Bio-
logic Formulation
While developing of biopharmaceuticals high protein concentration are commonly encoun-
tered and pursued for several reasons6. The reasons to develop high protein concentration
are target requiring high dose and easy delivery approaches for convenience to patient6.
Antibodies are large and large proteins require large mass for therapeutic dose. Develop-
ing moderate to high concentration formulations is challenging as there are many problems
encountered like high viscosity, protein instability due to formation of soluble and insoluble
aggregates during formulation process and storage. These hamper the manufacturability,
deliverability, stability and self life of the product6. High viscosity also requires high injec-
tion force which is painful to the patient. Thus addressing this issue has been one of the
main challenge pharmaceutical companies are struggling with6. Efficient dosing of therapeu-
tic antibodies often requires concentrations in excess of 100 or even 200 mg/ml. However,
many antibodies have a sharp rise in the viscosity that renders production and delivery pro-
hibitive at these concentrations. Unfortunately, this problem is only apparent late in the
development pipeline when it is not feasible to alter the sequence to mitigate the viscosity.
A better approach would be to choose low viscosity target molecules early in the pipeline
so that the problem can be avoided altogether. To achieve this goal it is necessary to un-
derstand how the minor sequence perturbations within the complementarity determining
regions contribute to the many-body interactions responsible for the elevated viscosity. The
sharp rise in antibody viscosity has several characteristics that are very different from solu-
tions of rigid bodies. First, the onset of the nonlinear regime occurs at volume fractions on
the order of 5–10% which is much less than the jamming transition for comparably shaped
rigid bodies (e.g. 58% for spheres). Secondly, the viscosity of a given molecule correlates
well with attractive intermolecular interactions5. While this is intuitively reasonable, the
viscosity of a flocculated solution is primarily a function of the solute volume fraction. The
volume fraction does not change upon aggregation, although entrained water cavities could
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account for a factor of 2 or 3 increase. To explain these discrepancies, we recently proposed
an alternative model in which transient interactions between antigen binding domains result
in long, flexible antibody complexes1. These complexes entangle with each other giving the
solution the viscosity characteristic of a semi-dilute polymer solution. Up to certain concen-
tration the increase in viscosity is small but as soon as the concentration increases to certain
value the mAbs show rapid increase in viscosity.
1.4 Introduction of Shear Thinning and Shear Thick-
ening
There are two types of fluids newtonian and non-Newtonian. Those fluids in which the
viscosity of fluids remains constant with the shear strain are called Newtonian fluids and
those fluids in which the viscosity of fluids changing with the shear strain are called non-
Newtonian fluids. In Newtonian fluids the relation between shear stress and shear rate is
linear with constant of proportionality being the coefficient of viscosity. In non-Newtonian
fluids the relation between shear stress and shear rate is different and we can’t define the
coefficient of viscosity. The relationship between shear stress and the viscosity is given by
τ = η ∗ γ (1.1)
where τ is the shear stress, η is the viscosity and γ˙ is the shear rate. The example of
Newtonian fluids are water, alcohol, glycerine etc. In these fluids shear strain does not affect
the viscosity. The example of Non-Newtonian fluids are ketchup, custard, starch, toothpaste
etc. Non-Newtonian fluids can be categorized into two ways, those fluids whose viscosity
increases with the shear rate are called shear thickening fluids and those fluids whose viscosity
decreases with the shear rate are called shear thinning fluids. Example of shear thickening
fluids are corn starch, custard etc. When you pour water in corn starch and shear it after
sometime you will get a thick fluid and continuous shearing will eventually make it hard.
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In shear thinning fluids the contiuous shearing will decrease the viscosity. Example of shear
thinning fluids are blood, ketchup, paint etc. The ketchup is thick inside the bottle but when
you shear it becomes thin and flows.
Figure 1.2: Relationship between stress and viscosity. Shear thinning fluids show decrease
in viscosity with stress while shear thickening fluid show increase in viscosity with stress
1.5 Classification of Polymer and Polymer Model of
Antibody Viscosity
Grassley16 has classified polymer solutions into five different regimes(see figure 1.5) according
to concentration and molecular weight. There are theories for three of these regimes-Zimm
model for dilute solutions, Rouse model for concentrated but not entangled solutions and
Doi Edwards model for concentrated entangled solutions. Other two regimes are mixed the-
ories by applying Rouse model to semidilute unentangled solutions17–19 and Doi-Edwards
semidilute entangled solutions9;17;18. Broadly speaking the polymer solutions are classified
into three different categories according to the extent of the interaction- dilute polymer so-
lutions, semidilute polymer solutions and concentrated polymer solutions. Those solutions
which have concentration less than the overlap concentration(c∗) are called dilute polymers,
those with concentration near the overlap concentration are called semi dilute and those
6
Figure 1.3: classification of polymers in terms of concentration and molecular weight which
shows different regimes and each regimes can be explained by different theories16
with greater concentration than the overlap concentration are called concentrated polymer
solutions11.(see figure 1.6)
Figure 1.4: classification of polymer solutions according to the extent of interaction of
polymer chains (de Gennes11)
The dynamics of the polymer solutions is limited by entanglements. In dilute solutions there
is no entanglement. In concentrated solutions molecules are entangled hindering the flow. In
semidilute solutions the entanglement is just started. There are different polymer theories
which have been explained briefly below-
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1.5.1 Rouse Model
The Rouse Model describes the dynamics of the ideal chain. It is applicable to short chains
which consists of gaussian worm-like chain. It excludes the hydrodynamic interaction. A
long chain is divided into short chains which obey the gaussian statistics with end to end
distance aR. Then these chains are attached with imaginary springs and the restoring force
f as a that of a whole chain is given by
f =
3kBT
< δr2 >
δr (1.2)
where δr is the mean square displacement.
Figure 1.5: Schematic view of Rouse model. The beads(N=13) are connected by
springs(picture source wikipedia)
The finite chain can be divided into different subsections with indistinguishable units
to get the different Rouse modes. The motion of the chain is superpostion of independent
intra-chain or Rouse Modes which can be found by the Fourier transformation (M.Doi9). I
have not calculated the Rouse modes and the diffusion coefficient but included the results9.
The diffusion coefficient is given by
D =
kBT
Nζ
(1.3)
and the Rouse relaxation time for the zeroth mode is given by9
τr =
ζN2b2
3Π2kBT
(1.4)
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where ζ is the friction coefficient on the chain due to the surrounding medium. From this
relation we find D ∼ N−1 and τr ∼ N2. Since N is proportional to the molecular mass,
we have D ∼ M−1 and τr ∼ M2. These are not consistent with the experimental results.
Experiments in dilute conditions gives D ∼M−1/2 and τr ∼M3/2. This failure is because we
excluded hydrodynamic interaction. Thus Rouse model is regarded inappropriate in dilute
solutions.
1.5.2 Zimm Model
Zimm model is applicable to polymers in dilute solutions. Zimm model takes account into
hydrodynamic drag force on the polymer due to solvent. Force acting on the polymer creates
flow field with net components in the same direction as the primary force. We can use Stokes’
Figure 1.6: Hydrodyanamic force in zimm model. Force acting on polymer coil creates flow
field with net component in the same direction as the primary force. Here the bigger arrow
is the primary force and other arrows are the flow in the direction of the primary force. The
figure is only to show the hydronamic drag
law which gives
ζ = 6ΠRη (1.5)
where ζ is the friction coefficient. Consider polymer coil as group of particles or beads.
Group of particles move more easily than the isolated particles. In Zimm model group of
the whole coil moves as one including the solvent molecules. The effective hydrodyanamic
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radius of the coil is given by
Rh = ζp/6Πη (1.6)
where ζp is the friction of coefficient of the polymer which is given by
ζp = 4ΠηRg (1.7)
Einstein’s theory gives diffusion coefficient to be
D = kBT/ζp ⇒ D ≈ N−0.6 (1.8)
These results are consistent with the experimental results in dilute polymer solutions.
1.5.3 Reptation Model
Reptation is the thermal motion of very long linear entanglement macromolecules in polymer
melts or concentrated polymer solutions.7. Reptation is used as a mechanism to explain vis-
cous flow in an amorphous solution.8. Reptation suggests the movement of the entanglement
polymer chain as that of snakes slithering through one another.8;14. Long chain polymers
contain entanglements which constrain the movement and thus their response to mechanical
deformation. The chain only can move in the longitudinal direction and its transverse mo-
tion is restricted. The entanglements can be thought of long bars which restrict the chain
in two dimensions and the diffusion is only along its length. This wriggling motion called
reptation governs the time taken by the polymer chains to respond to any applied stress
which leads non-linear response. This non-linear behaviour can be explained by the scaling
arguments(see calculations below) based on time taken for the chain to escape the tube
confining entanglements.
The mobility µtube of the tube is given by
µtube = µ1 ∗ /N (1.9)
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Figure 1.7: The figure in the left shows entanglement. The figure in the right shows trans-
verse motion is restricted and motion is only along its length
Figure 1.8: motion of chain along the tube showing the initial conformation of the primitive
chain and the tube which we call the original tube. Here due to entanglement we can assume
the polymer chain moves along the virtual tube.
where µ1 is the mobility of the chain segment.
The tube diffusion coefficient can be calculated as
Dtube = µ1T/N = D1/N (1.10)
The time taken by for a chain to diffuse over a length comparable to that of tube is
Tt = L
2/Dtube = NL
2/D1 ∼ N3 (1.11)
The prediction that terminal time and hence the shear viscosity scales like N3 is in
reasonable agreement with the experiment N3.3. Reptation theory gives the relationship
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between the molecular mass and the relaxation time.9. The relaxation time τ is given by
τ ∼M3 where M is the molecular mass9.
Here we treat the antibodies as highly flexible molecule. The goal is to determine if the
elongated shape and flexibility has effect in the viscosity. The antibody viscosites are found
consistent with the reptation dynamics as would be expected in the semidilute solution of
polymers10.
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Chapter 2
Different binding Models of antibody
2.1 Introduction
Numerous experimental studies have established that the steep rise in the viscosity of an-
tibody solutions is caused by the formation of supramolecular complexes of antibodies5.
These complexes increase the viscosity either through polymer-like entanglements or by the
formation of an extended network10. Regardless of the viscosity mechanism, it seems clear
that the first step toward predicting antibody viscosity is to understand the size and shape
of the complexes. Antibodies are Y-shaped molecules so there are different ways in which
the molecules can interact. In fab−fab binding the head of one molecule binds with the head
of another molecule which we call here as fab − fab or head-head binding. Similarly head of
one molecule can bind with the tail of another molecule which we call fab − Fc interaction
or head-tail binding. Similarly tail of one molecule can bind with tail of another molecule
which we call Fc−Fc binding or tail-tail binding. The different binding models are described
below.
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2.2 Binding models
Here we derive the equilibrium distribution of antibody complexes. The input parameters
for our calculation are two-body binding constants that can be directly measured by tech-
niques like SPR. We consider two binding constants in the model corresponding to Fab-Fab
interactions and Fab-Fc interactions. In the following we consider each of these interactions
separately before presenting a theory that accounts for both interactions simultaneously.
2.2.1 Head to head binding
First we consider the association between two Fab domains, which we refer to as “head
to head” (HH) binding. As discussed previously, HH binding results in the formation of
linear chains of antibodies [Schmit et al. 2014]. The two simplest HH complexes are shown
schematically in Fig. 2.1. In these cartoons model the head of one polymer antibody attaches
with the head of another and so on.
Figure 2.1: The head to head binding model describes antibodies that aggregate by forming
reversible contacts between Fab fragments. The two simplest structures are the dimer (left)
and trimer (right). Further aggregation results in the formation of long chained antibodies.
The equilibrium constant for HH association is defined by
k =
cHH2
c21
(2.1)
where cHH2 is the concentration of dimers formed by HH association. Therefore, the con-
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centration of dimers is kc21, the concentration of trimers is k
2c31, etc. Summing over all HH
complexes, the grand partition function is
qHH = c1 + c
2
1k + c
3
1k
2 + . . . (2.2)
where the monomer concentration plays the role of the fugacity c1 = e
µ/kBT . The partition
function can be written as the recursion relation
qHH = c1(1 + kqHH) (2.3)
The two terms on the right hand side of Eq. 2.3 correspond to the two possible states for an
antibody ‘head’. First, the head can be unbound, which terminates the complex and results
in the factor of 1. Secondly, the head can be bound to another molecule which, in turn, can
be bound to another, and so on. In the grand canonical formalism, the number of molecules
in this chain can range from one to infinity. Since this is the same range of sizes considered
in the partition function, the sum of possible outcomes can be replaced by the factor qHH
on the right hand side of Eq. 2.3. Rearranging Eq. 2.3, we arrive at a simple expression for
the partition function
qHH =
c1
1− kc1 (2.4)
2.2.2 Head to tail binding
The second model of binding we consider is the association of a Fab domain with a Fc domain.
We refer to this as “head to tail” (HT) binding. There are two possible dimers resulting
from HT binding which are shown in Fig. 2.3 and 2.4.
We define s as the equilibrium constant for HT binding. The partition function for
complexes formed entirely by HT binding can be written as the following recursion relation
qHT = c1(1 + 2sqHT + s
2q2HT ) (2.5)
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Figure 2.2: head tail binding model describes antibodies that aggregate by forming contacts
between Fab − Fc fragments. In the above figure head of of antibody attaches with tail of the
other to form dimer
The three terms correspond to the possible head binding states of a single molecule. The
first term is the state where both heads are unbound, the second term is when only one of
the heads binds to another molecule, and the third term corresponds to the state where both
heads binding to other molecules. Since each bound molecules can initiate a cluster of any
number of molecules, this introduces factors of qHT . The recursion relation can be solved for
qHT
qHT =
1− 2sc1 −
√
1− 4sc1
2s2c1
(2.6)
which has the Taylor expansion
qHT = c1 + 2c
2
1s+ 5c
3
1s
2 + . . . (2.7)
This predicts 5 different trimer states which can be diagrammed as follows
2.2.3 Tail to tail binding
A third mode of binding, association between Fc domains, is also possible. While “tail
to tail” (TT) binding may be responsible for the formation of larger structures that are
important for the viscosity, we omit it from the current model. TT binding will be included
in future versions of the theory.
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Figure 2.3: Head tail binding for trimer is shown in the figure in which head of one antibody
attach with tail of another and so on. The structure shown is trimer. Further aggregation
in the similar way forms long chain of antibodies
2.2.4 Mixed binding
We now compute the distribution of complexes formed by molecules that can bind by both
HH and HT interactions. We expect that this model will capture most of the variability
between different antibody sequences and will be quantitatively accurate under conditions
where TT binding is weak.
The partition function for the mixed HH/HT model is given by the recursion relation
q = c1(1 + sq + kq)(1 + sq) (2.8)
To derive this formula, we assume the existence of a molecule in each cluster that has an
unbound head. The partition function is a summation over the possible states of molecules
bound to this starting molecule. Specifically, we need to account for the binding states of the
remaining head and tail. The first term in Eq. 2.9 represents the states for the remaining
head which can be unbound, bound to the tail of another molecule, or bound to another
head. The second term represents the states of the tail, which can be unbound or bound to
a head. Since each binding event ties up one head on the following molecule, the summation
over molecules bound to each site is equivalent to a factor of q. Eq. 2.9 is a quadratic
17
equation for q which can be solved to give
q =
1− c1k − 2c1s−
√
1− 2c1k + c21k2 − 4c1s
2(c1ks+ c1s2)
(2.9)
This has the Taylor expansion
q = c1 + 2c
2
1s+ c
2
1k + c
3
1k
2 + 5c31s
2 + 5c31sk + . . . (2.10)
where the enumerated states are schematically represented in figure ??
Figure 2.4: HT and HH model. They either bind head head, they can bind head tail and
they can bind either head or tail in the same molecule as shown in figure.
In these structures we have shown all types of binding. For dimers there can be either
head head binding or head tail binding. While we go to higher structure like trimers and
above we see either head of one antibody binds with tail of other or head of one antibody
with head of other and so on (see Fig 2.4).
The average size of the structures is given by
< n >= c1
dln(q)
dc1
(2.11)
where c1 can be found from the total concentration ctot = c1dq/dc1. Once we find the average
size we can find the viscosity which is described in chapter 3. To calculate the distribution
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of complexes, we first express the equilibrium constants in terms of the antibody mass m
and the free energy of the binding interactions
k =
1
m
ev1 (2.12)
s =
1
m
ev2 (2.13)
where v1 and v2 are the free energies for HH and HT binding, respectively, in units of kBT .
Fig. 2.6 plots the average size of the antibody complexes as a function of the binding
interactions at a constant antibody concentration of 150 mg/ml. Very little aggregation
occurs for free energies of 0 or 3 kBT , but significant association occurs when the energy
reaches 6 kBT . The effect is particularly dramatic when HT binding is strong because this
allows the antibodies to form highly branched structures with high entropy (see graphs 2.5
and 2.6).
Figure 2.5: average size as function of binding energy. The size is large particularly when
HT binding is strong.
The following plots show the concentrations of monomers, dimers, and trimers as a
function of binding energies. At high binding energies all three species show a drop in
concentration indicating that most of the protein in the system is tied up in larger aggregates.
The different binding models of the antibody is explained above. In the following chapter
we consider only the head-head binding of the antibody and leave other types of binding for
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Figure 2.6: concentration of monomers, dimers and trimers as function of binding energies.
At high binding energy all the species show a drop in concentration indicating most of the
protein in the system is tied up to larger aggregate
future work.
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Chapter 3
Shear thinning in Monoclonal
Antibodies
3.1 Introduction
Due to the growth of monoclonal antibody therapy the viscosity behaviour of mAbs are
one of the great interest and topic of research12. While injecting the protein drugs to the
patients, force is needed to push the antibody drug through the needle. The antibodies act
as shear thinning fluid which means upon shearing the viscosity of antibody decreases.
3.2 Model
We begin by summarizing previous theory for the zero shear viscosity10. According to the
reptation theory polymer is confined to an effective tube due to constraints imposed by
neighbouring molecules. As time passes, the polymer diffuses along the tube (”reptates”),
so after some time the ends of the polymer are disengaged from the original tube while some
part in the middle is still confined in the tube. We take antibody as polymer in which fAb
region of one antibody binds with the fAb region of another.(see figure below).
After a strain is applied to the solution, the confining tube will be deformed. The
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Figure 3.1: Antibody forms long polymer structure in head head binding. Here fab region of
antibody binds with fab region of another antibody to form long elongated structure. Reprinted
with permission from Schmit, J.D.: He,Feng; Entanglement model of antibody viscosity.
Copyright 2014. The Journal of Physical Chemistry
subsequent reptation motion will establish a new equilibrium tube and only the polymer
segments confined to the original deformed tube will contribute to the stress. So the stress
after strain dγ in time dt is given by
σ ∼ G(t)dγ (3.1)
= G(t)
dγ
dt
dt (3.2)
= G(t)γ˙dt (3.3)
whereG is the elastic modulus. Thus we can write the instantaneous viscosity as ηinstantaneous =
σ
γ˙
= G(t)dt. Only the segments of this deformed tube contribute to the stress so the relax-
ation modulus is proportional to the fraction ψ(t) of the polymers still confined in the tube.
G(t) = G0N ∗ ψ(t) (3.4)
Here G0N is some constant and ψ(t) is the fraction of the polymer still confined in the
tube. As the system evolves after the application of strain, the molecules will release their
entanglements by diffusion. Therefore, the stress relaxation will occur with a characteristic
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timescale of the molecular diffusion. In an entangled solution this diffusion is described by
the reptation time, τrep, so
ψ(t) = e
− t
τrep (3.5)
The zero shear viscosity of the antibody is given by the ω = 0 mode of the fourier transform
η0 =
∫ ∞
0
ηinstantaneousdt (3.6)
=
∫ ∞
0
G(t)dt (3.7)
= G0N
∫ ∞
0
dtψ(t) (3.8)
= G0N ∗ τrep (3.9)
The elastic modulus gives the energy stored in the network. This can be estimated by
counting the number of intermolecular entanglements, each of which is expected to store an
energy on the order of kBT . A scaling calculation to find G
0
N is described below.(M. Doi
9)
Consider a original chain consisting of bond length b. The statistical property of the Gaussian
chain doesn’t depend on the local structure of the chain so instead of the original Gaussian
chain with bond length b and consisting of N segments, we consider new chain consisting
of N ‘ = N/λ segments with bond length
√
λb(see figure below). The transformation to the
new chain from the old one is the change is parameter N −→ N/λ, b −→ bλν , c −→ c/λ
The overlap concentration c∗ 9 is given by
c∗ ' N/(R(0)g )3∗ ∼
N1−3ν
b3
(3.10)
where R
(0)
g ' N ν b is the radius of gyration. We use the dimensional analysis to find G0N .
The relevant parameters in the problem are b,c,N ,kBT , so we write
G0N =
c
N
kBTF (cb
3, N) (3.11)
where F (cb3, N) is the parameter to match the dimension. After using the above transfor-
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mation we get
G0N =
c
N
kBTF (cb
3λ3ν−1), N/λ) (3.12)
Since G0N is invarient under the above transformation we have
c
N
kBTF (cb
3, N) =
c
N
kBTF (cb
3λ3ν−1), N/λ) (3.13)
This condition is satisfied only when
G0N =
c
N
kBTF (cb
3N3ν−1) =⇒ G0N =
c
N
kBTF (
c
c∗
) (3.14)
Here by assuming power law, F (
c
c∗
) = (
c
c∗
)x In semidilute regime it is independent of N. so
we write
(3ν − 1)x− 1 = 0⇒ x = 1
3ν − 1 (3.15)
This gives
G0N ∼
c
N
kBT
( c
c∗
) 1
3ν−1
(3.16)
It is well known that the reptation time is proportional to N3 which I have described in chap-
ter 1. Here ν ' 3/5 is the Flory exponent, b is the bond length, c is the total concentration.
Plugging equation 3.15 and equation 3.16 into equation. 3.9 we get
η0 ∼ c 33ν−1N3 (3.17)
Here N is proportional to the aggregate size which can be calculated assuming that the
antibodies form linear aggregates by the association of the antigen binding domains10. The
calculation of N is based on head-head or fAb-fAb binding of the antibody polymer. I
have calculated the partition function of the head-head binding of the antibody polymer in
chapter 2 which I will recall here.
q =
c1
1− kc1 (3.18)
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Here c1 is the monomer concentration. The chemical potential of the monomer state with
zero free energy is given by10
µ = kBT lnc1 (3.19)
The total protein concentration is given by
c = c1
dq
dc1
=
c1
(1− c1k)2 (3.20)
we can solve this equation to find the monomer concentration c1.
c1 =
1
2k2c
(1 + 2kc−√1 + 4kc) (3.21)
The average assembly size is given by
< N >=
c
q
(3.22)
Thus the final expression for assembly size is
N =
2 ∗ k ∗ c√
1 + 4 ∗ k ∗ c− 1 (3.23)
where k is the equilibrium constant for antibody dimerization. Thus finally we have the zero
shear viscosity as
η0 = P ∗ c15/4 ∗ ( 2 ∗ k ∗ c√
1 + 4 ∗ k ∗ c− 1)
3 (3.24)
where P = 5.8 ∗ 10−8cP (mg/ml)−3.75 10 is a fitting constant that can not be obtained from
scaling theories. Eq. 3.24 predicts that the viscosity varies with c15/4 at low concentration
and c21/4 at high concentration. In practice, the antibody complexes are too short at low con-
centration to obey scaling relations and the observed exponent is closer to 2.7. As expected,
the agreement with the scaling theory improves at high concentrations as the effective size
of the antibodies increases.10
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3.3 Introduction Of Shear
The viscous response of a polymer solution in the presence of shear is the product of two
relaxation mechanisms. First, the shear will tend to stretch out the polymers by deforming
the “tube” of entanglements that constrain them (T. Milner15). This will cause the polymers
to contract back to their equilibrium size along the tube.
Figure 3.2: chain retraction to equilibrium after strain. Here figure i shows the chain
entangled inside the tube. Red circle denotes the entanglement points. After shear is applied
the chain is elongated (figure ii) and as chain retracts the entanglements a,b,c,d are lost
(figure iii). The entanglements e and f again come back as chain reptates (figure iv).
This contraction releases entanglements and occurs on a timescale on the order of the
Rouse time. Second, the polymers will undergo reptational diffusion to establish a new
tube with the original number of entanglements. Therefore, these two processes oppose each
other with the chain retraction releasing entanglements and reptation restoring them. In
the scaling limit the Rouse time is proportional to R2 so it can be treated as instantaneous
compared to the reptation time which is proportional to R3. Since our antibody complexes
are too short for the scaling behavior to dominate, it is worth checking that this hierarchy
is still appropriate. The Rouse time is given by
τr =
6piηaN2b2
3pi2KBT
(3.25)
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here, L = Nb (b is the length of chain) and L = 3Na where a = 1.8 nm is length of the
arm of chain. After calculation we get τr = 2.6 ∗ 10−7s for monomers, τr = 1.04 ∗ 10−6s for
dimers, and τr = 2.08 ∗ 10−6s for trimers.
For the reptation time we estimate
τrep ' L
2
D
(3.26)
where L is length of the polymer and D is the diffusion constant with units m2/s. The
diffusion constant is proportional to the number of segments in the polymer and the diffusion
constant of a single segment. In our case, we identify a polymer segment with a single domain
in the antibody. We can estimate the domain diffusion with the Stokes-Einstein equation
Ddomain =
kBT
6piηR
(3.27)
here η = 10−3kg/(m.s), 2R = 5.5nm is the diameter of an IgG domain. With these values
we get Ddomain = 3.99 ∗ 10−11m2/s. Thus the longitudinal diffusion of polymer antibody
is described by D = Ddomain/(3N). length L of polymer is L = 3N × 5.5nm. With these
substitutions we can rewrite the reptation time above as
τrep =
L2
D
=
(3NR)2
Ddomain/(3N)
(3.28)
This takes the value τrep = 1.66 ∗ 10−4 s for a dimer (N = 2),τrep = 5.61 ∗ 10−4 s for a trimer
and τrep = 1.33 ∗ 10−3 s for a tetramer.
We conclude that it is still a good approximation to treat the Rouse time as much faster
than the reptation time. The question, then, is how many entanglements does the chain
retraction remove before the reptation relaxation restores them? To calculate this we need
to know the amount the confining tube has elongated over the course of the reptation time.
This is given by dγ = γ˙τrep, where γ˙ is the shear rate. We write the elastic modulus as
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G(dγ) = G0h(dγ) where h is the damping function which describes the fraction of remaining
entanglements. The damping function can be estimated as follows15. If n is tangent vector of
the isotropic tube and is deformed by the deformation gradient E then the previous tangent
vector is no longer a unit vector but it is n′ = E ·n. Its length is n′2 = n ·ET ·E ·n. In shear
the material is deformed which is characterized by the single parameter γ. All the stress
components vanish except the diagonal components. So the deformation tensor under shear
is
E =

1 γ 0
0 1 0
0 0 1
 (3.29)
Thus the root mean squared tube length increases by factor of (1+γ2/3)
1
2 immediately after
strain. After retraction the length of the tube is reduced by a fraction (1 + γ2/3)
−1
2 . Thus
we can estimate h(dγ) as h(dγ) = (1 + γ2/3)−
1
2 .
The stress level after a deformation dγ is given by
σ = G(dγ)dγ (3.30)
= G0h(dγ)dγ (3.31)
and the viscosity is
η =
σ
γ˙
= Gτreph(γ˙τrep) (3.32)
which gives
η =
η0√
1 +
γ˙2τ2rep
3
(3.33)
As with our original model10, the risk with this analysis comes from the size of the
antibody complexes which are too short for us to blindly trust polymer scaling calculations.
An alternative model would be to treat the antibodies as rigid rods, which can still entangle
and diffuse in a reptation-like manner, but cannot contract or expand. This model (multibead
rod model) would give a damping fraction that scales like γ−1/2 21 instead of the γ−1
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3.4 Model Behaviour
In our theory the differences between antibody molecules are contained in the equilibrium
constant k. Increasing k corresponds to more attractive interactions which will result in
larger antibody complexes. This has two effects on the shear dependent viscosity. First,
larger complexes are able to form more entanglements, which will increase the zero shear
viscosity predicted by Eq. 3.24. This can be seen by the height of the plateaus at low
shear in Fig. 3.2. Secondly, the increased length will increase the reptation time of the
polymers, which shifts the onset of shear thinning behavior to lower shear rates. This is
because the slower diffusion prevents these complexes from re-establishing an equilibrium
number of entanglements on the timescale of tube deformation. From Eq. 3.33 we can see
that shear thinning will happen only when γ˙ ∗ τ ≥ 1
Figure 3.3: Effect of antibody-antibody affinity on shear dependent viscosity. More attractive
antibodies form larger complexes which have higher viscosity at low shear. However, these
complexes also have a larger reptation time which shifts the shear thinning onset to lower
shear rates. This is just the prediction curve with the k value’s 6.23 ∗ 10−2,4.7 ∗ 10−2 and
3.02 ∗ 10−2 in units of ml/mg respectively
3.5 Fitted with experiment
Now I try to fit equation 3.24 with the Genentech data5. The fitted plot for Mab1 at
150mg/ml for different NaCl concentration are shown in figure 3.3.
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Figure 3.4: Effect of omM, 25mM and 50mM NaCl from top to bottom on the viscosity of
mAbs. The respective k values are 2.79 ∗ 10−2, 1.90 ∗ 10−2 and 1.19 ∗ 10−2
Fits capture correlation between plateau height and shear thinning onset. Mab1 is seen
affected by the introduction of NaCl. I fitted extracted data with equation 3.24. We know
Mabs have same IgG1 framework and they only differ in CDR sequence. So we can say the
sequence changes vary the surface charge distribution which change the overall interaction
behaviour. When γ = 0 equation 3.24 gives equation 3.15 i.e. the zero shear viscosity. We
have experimental data for viscosity and concentration from Yadav’s data6. When I fit these
we get the curves which are fitted ok at high concentration. (see figure 3.4)
Figure 3.5: Zero shear viscosity fitted with head to head model using yadav’s data5 for
different mAbs. Fits are not good at low concentration but are ok at high concentration
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This curve in figure 3.4 is compared with data which I extracted from Yadav et al5. Fits
are good at low concentration but not at high concentration.
3.6 Effect of temperature
We can also describe the effect of temperature on the viscosity of Mabs. The increase of
temperature is going to decrease the binding energy which in turn decreases the reptation
time. So as we increase the temperature the shear thinning occurs at higher shear rate (see
fig. 3.5). At lower temperatures the binding energy is high that is why reptation time is
high and shear thinning is seen at relatively low shear rates.
Figure 3.6: Effect of temperature at concentration 200mg/ml (Top to bottom 5, 10, 15 and
20 degrees respectively) for mab15 and the values of k’s are 9.32 ∗ 10−2, 7.43 ∗ 10−2, 5.35 ∗
10−2, 4.03 ∗ 10−2 in units of ml/mg respectively
3.6.1 Explanation of fit in figure 3.5 and figure 3.6
At first I fit the equation
η = Pc15/4(1 +
2kc√
1 + 4kc− 1)
3(1 +
γ2X2( 2kc√
1+4kc−1)
6
3
)−1/2 (3.34)
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where τrep = Xn
3 and n = 2kc√
1+4kc−1
1. Here the reptation time I found was from sum of the
square errors. I fitted four different viscosity vs shear data and the sum of square errors will
give me constant X. The value of X found is 1.8 ∗ 10−5.
Again I fit the equation 25 using the value of X and I find k’s. These k’s are used in curve
3.5 (see caption in curve 3.5 for values of k).
In the same way explained above I find k for figure 3.6. Now to account the temperature
dependence of the binding affinity I fit the equation
k = m−1w e
−(h−Ts)/kbT (3.35)
where mw is the molecular weight factor(mw = 142KDa). Then I find the fitted values of
h and s. Here the motive is to reduce the parameters. Now I replot the curves with these
fitted values of h and s.
Figure 3.7: Effect of temperature at concentration top to bottom 5, 10, 15 and 20 degree
celsius respectively. The fitted values of h and s found from fitting were -37.03 KJ/Mole and
-54 J/K/Mole respectively. The difference with figure 3.5 is in terms of parameters only. In
figure 3.5 there are four k parameters while in figure 3.6 I reduced the parameters and fitted
in terms of h and s (four k parameters are reduced to two parameters h and s)
Now let’s check the power law for rod model from the experimental data21. This gives
the power law coefficient to be -0.5.
When I check the power law exponents for the mAb data for temperature dependence
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Figure 3.8: fit for linear datas of rod model21 and temperature dependent data. The expo-
nents for rod model is -0.54 and that for temperature dependent data is -0.30
and NaCl dependence I get the power law coefficient to be -0.30 and -0.20 respectively (see
figures).
Figure 3.9: Fit to get power law for NaCl dependence viscosity mAb. The exponent is -0.20
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3.7 Conclusion
The reptation time and the shear thinning is captured by binding energy k. When k increases
the zero shear viscosity increases and the shear thinning occurs earlier. With the decrease in
k, the value of the zero shear viscosity decreases and the shear thinning occurs at later time.
We still need correct exponents to describe the theory. We have used the linear polymer
model for the antibody which might have not given us the correct results. The failure of
the prediction is because we considered antibody as flexible linear polymer. They might be
short and branching might happen. In future we plan to work on the branching model of
polymer and expect the correct exponents.
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